<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293410</url>
  </required_header>
  <id_info>
    <org_study_id>J0561 CDR0000456431</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0561</secondary_id>
    <secondary_id>JHOC-00000845</secondary_id>
    <nct_id>NCT00293410</nct_id>
  </id_info>
  <brief_title>Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders</brief_title>
  <official_title>Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Adults and Children With Relapsed or Refractory Acute Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as clofarabine and cyclophosphamide, work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of clofarabine and&#xD;
      cyclophosphamide in treating patients with relapsed or refractory acute leukemia, chronic&#xD;
      myelogenous leukemia, or myeloproliferative disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the feasibility and tolerability of administering clofarabine and fractionated&#xD;
           cyclophosphamide in patients with relapsed or refractory acute leukemia, chronic&#xD;
           myelogenous leukemia, or high-risk myeloproliferative disorders&#xD;
&#xD;
        -  Determine the maximum tolerated dose of clofarabine and fractionated cyclophosphamide in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the toxic effects of these drugs in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Obtain preliminary data of biologic and pharmacodynamic effects of this regimen on&#xD;
           marrow and circulating leukemic blasts in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients are stratified according to age (adult vs&#xD;
      child).&#xD;
&#xD;
      Patients receive cyclophosphamide IV over 2 hours on day 0. Patients then receive clofarabine&#xD;
      IV over 2 hours and cyclophosphamide IV over 2 hours on days 1-3 and 8-10. Treatment with&#xD;
      clofarabine and cyclophosphamide repeats every 28 days for at least 2 courses in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of clofarabine and cyclophosphamide until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that&#xD;
      at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 10 patients&#xD;
      are treated at the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clofarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed leukemia or myeloproliferative disorders, including 1 of the&#xD;
             following:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) of any subtype&#xD;
&#xD;
                    -  Treatment-related AML OR AML evolving from myeloproliferative disorders&#xD;
                       (MPD) or transformed from myelodysplastic syndrome&#xD;
&#xD;
               -  Acute lymphocytic leukemia&#xD;
&#xD;
               -  Acute progranulocytic leukemia&#xD;
&#xD;
                    -  Must not be eligible for arsenic or retinoic acid therapy&#xD;
&#xD;
               -  Chronic myelogenous leukemia in accelerated phase or blast crisis&#xD;
&#xD;
               -  High-risk MPD, including any of the following:&#xD;
&#xD;
                    -  Myelofibrosis&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia with 5%-19% blasts&#xD;
&#xD;
                    -  Relapsed or refractory juvenile myelomonocytic leukemia&#xD;
&#xD;
          -  Relapsed and/or refractory disease with progressive disease since last therapy&#xD;
&#xD;
               -  No more than 3 prior induction regimens with cytotoxic agents for adults&#xD;
&#xD;
               -  Must be in second relapse for patients &lt; 21 years of age&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2 (for adults) OR Lansky 50-100% (for pediatric patients)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL (may be elevated due to hemolysis in adult patients)&#xD;
&#xD;
          -  AST and ALT ≤ 5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL (for adults)&#xD;
&#xD;
          -  Normal renal function (for pediatric patients)&#xD;
&#xD;
          -  Cardiac function normal as measured by MUGA scan or echocardiogram&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for at least 6&#xD;
             months after completion of study treatment&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active graft-versus-host disease ≥ grade 2&#xD;
&#xD;
          -  No active, uncontrolled infection&#xD;
&#xD;
          -  No fever&#xD;
&#xD;
          -  No unstable CT scans of the lungs, sinuses, or abdomen within the past 4 weeks&#xD;
&#xD;
          -  No arrhythmias (other than atrial flutter or fibrillation) requiring medication&#xD;
&#xD;
          -  No dyspnea at rest or with minimal exertion&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No history of severe coronary artery disease&#xD;
&#xD;
          -  No other significant concurrent disease, illness, or psychiatric disorder that would&#xD;
             compromise patient safety or compliance or interfere with consent, study&#xD;
             participation, follow up, or interpretation of study results&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Must have recovered from all acute toxic effects from prior treatment&#xD;
&#xD;
          -  More than 30 days since prior investigational cytotoxic agents&#xD;
&#xD;
          -  At least 3 days since prior azacitidine, thalidomide, hydroxyurea, imatinib mesylate,&#xD;
             or interferon&#xD;
&#xD;
          -  At least 1 week since prior growth factors except epoetin alfa&#xD;
&#xD;
          -  More than 3 weeks since any other prior anticancer therapy&#xD;
&#xD;
          -  No concurrent chemotherapy, radiotherapy, or immunotherapy&#xD;
&#xD;
          -  No other concurrent anticancer investigational or commercial agents&#xD;
&#xD;
          -  No routine prophylactic use of a colony-stimulating factor (filgrastim [G-CSF] or&#xD;
             sargramostim [GM-CSF])&#xD;
&#xD;
               -  Therapeutic use of colony-stimulating factors may be considered at the discretion&#xD;
                  of the investigator&#xD;
&#xD;
          -  No prolonged use of corticosteroids to prevent or treat emesis or as a&#xD;
             chemotherapeutic agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith E. Karp, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>May 5, 2010</last_update_submitted>
  <last_update_submitted_qc>May 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2010</last_update_posted>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>childhood acute basophilic leukemia</keyword>
  <keyword>childhood acute monocytic leukemia (M5b)</keyword>
  <keyword>childhood acute eosinophilic leukemia</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>childhood acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>childhood acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>childhood acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute monoblastic leukemia (M5a)</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

